…
MedX Health Corp develops, manufactures, and markets skin related screening tools and phototherapy devices for pain relief and tissue repair in Canada, the United States, Europe, and internationally. The company offers SIAscopy, a medical device technology used to scan skin for suspicious moles and lesions; and phototherapeutic medical devices, which use light energy in lower-level laser and LED to provide treatment for pain and tissue damage in the rehabilitation market. It also provides scope kits, SIAscope, a clinical camera; and DermSecure, a telemedicine software application. In addition, the company offers MedX rehab console system, rehab portable laser, and home unit; OraLase, a dental PBM laser; and veterinary-specific lasers. MedX Health Corp was incorporated in 1999 and is headquartered in Mississauga, Canada.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
MedX Health Corp is a Canada-based company listed on the TSX Venture Exchange (MDX.V); publicly available details about its current operations are limited. Long-term growth may depend on commercializing its technology or service offerings, achieving market adoption and strategic partnerships.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
| Income before tax | -3.65M | -4.58M | -5.13M | -5.32M | -3.20M |
| Net income | -3.65M | -4.58M | -5.13M | -5.32M | -3.20M |
| Selling general administrative | 1.67M | 2.22M | 2.94M | 3.55M | 2.79M |
| Gross profit | 0.19M | 0.19M | 0.24M | 0.29M | 0.27M |
| Reconciled depreciation | 0.05M | 0.05M | 0.05M | 0.05M | 0.08M |
| Ebit | - | - | - | - | -3.03M |
| Ebitda | - | - | -3.81M | -4.49M | -3.06M |
| Operating income | -2.30M | -3.03M | -3.87M | -4.56M | -3.03M |
| Interest expense | 1.35M | 2.15M | 1.27M | 0.78M | 0.06M |
| Net interest income | -1.35M | -2.15M | -1.27M | -0.78M | -0.06M |
| Total revenue | 0.49M | 0.46M | 0.51M | 0.56M | 0.53M |
| Total operating expenses | 2.79M | 3.48M | 4.38M | 5.13M | 3.56M |
| Cost of revenue | 0.30M | 0.27M | 0.27M | 0.27M | 0.26M |
| Total other income expense net | - | 0.60M | 0.00M | 0.02M | -0.11M |
| Net income from continuing ops | -3.65M | -4.58M | -5.13M | -5.32M | -3.20M |
| Net income applicable to common shares | - | - | - | - | -3.20M |
| Breakdown | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
| Total assets | 0.88M | 0.69M | 0.68M | 0.73M | 0.73M |
| Total liab | 9.41M | 7.83M | 7.76M | 4.36M | 2.80M |
| Total stockholder equity | -8.52M | -7.14M | -7.08M | -3.63M | -2.07M |
| Other current liab | - | - | - | 0.62M | 0.59M |
| Common stock | - | - | - | - | 23.00M |
| Capital stock | 27.49M | 26.95M | 23.96M | 23.94M | 23.00M |
| Retained earnings | -54.50M | -50.85M | -46.27M | -41.14M | -35.81M |
| Cash | 0.16M | 0.14M | 0.14M | 0.11M | 0.04M |
| Total current liabilities | 8.33M | 6.95M | 6.88M | 1.97M | 2.57M |
| Net debt | 6.82M | 5.62M | 4.86M | 2.47M | 0.88M |
| Short long term debt | 5.90M | 4.91M | 4.12M | 0.19M | 0.68M |
| Other stockholder equity | - | - | - | - | 2.41M |
| Property plant equipment | - | - | - | - | 0.22M |
| Total current assets | 0.84M | 0.60M | 0.54M | 0.54M | 0.51M |
| Net tangible assets | - | - | - | - | -2.07M |
| Net receivables | 0.03M | 0.01M | 0.01M | 0.01M | 0.04M |
| Long term debt | 1.08M | 0.84M | 0.88M | 2.39M | 0.23M |
| Inventory | 0.38M | 0.34M | 0.38M | 0.37M | 0.37M |
| Accounts payable | 0.34M | 0.63M | 0.62M | 0.50M | 0.56M |
| Non current assets total | 0.04M | 0.09M | 0.14M | 0.19M | 0.22M |
| Capital lease obligations | 0.04M | 0.09M | - | - | 0.03M |
| Breakdown | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
| Investments | 0.00M | 0.00M | 0.00M | -0.02M | -0.01M |
| Change to liabilities | - | - | - | 0.00M | -0.13M |
| Total cashflows from investing activities | - | - | - | - | -0.01M |
| Net borrowings | 2.10M | 2.95M | - | - | -0.04M |
| Total cash from financing activities | 2.53M | 3.42M | 2.84M | 4.60M | 2.94M |
| Change to operating activities | - | - | - | - | -0.01M |
| Net income | -3.65M | -4.58M | -5.13M | -5.32M | -3.20M |
| Change in cash | 0.02M | -0.00M | 0.04M | 0.07M | 0.03M |
| Begin period cash flow | 0.14M | 0.14M | 0.11M | 0.04M | 0.01M |
| End period cash flow | 0.16M | 0.14M | 0.14M | 0.11M | 0.04M |
| Total cash from operating activities | -2.51M | -3.42M | -2.80M | -4.52M | -2.91M |
| Issuance of capital stock | 0.43M | 0.41M | 0.00M | 0.93M | 2.98M |
| Depreciation | 0.05M | 0.05M | 0.05M | 0.05M | 0.08M |
| Change to inventory | -0.04M | 0.16M | -0.01M | 0.00M | -0.13M |
| Change to account receivables | -0.02M | -0.06M | -0.13M | -0.03M | 0.02M |
| Other cashflows from financing activities | - | - | - | 0.22M | 0.22M |
| Change to netincome | - | - | - | - | 0.46M |
| Capital expenditures | 0.00M | 0.00M | 0.00M | 0.02M | 0.01M |
| Change in working capital | 0.19M | -0.13M | 1.02M | 0.04M | -0.26M |
| Stock based compensation | 0.14M | 0.31M | 0.33M | 0.23M | 0.35M |
| Other non cash items | 1.35M | 2.12M | 1.27M | 0.51M | 0.02M |
| Free cash flow | -2.51M | -3.42M | -2.80M | -4.53M | -2.91M |
Sector: Healthcare Industry: Medical Devices
|
Stock Name
|
Change
(CAD) |
Price
(CAD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| MDX MedX Health Corp |
-0.01 20.00% |
0.04 | - | 13.50 | 34.49 | - | 53.75 | -3.78 |
| TLT Theralase Technologies Inc. |
0.01 2.70% |
0.19 | - | - | 90.07 | 82.51 | 90.31 | -12.06 |
| CNVI Conavi Medical Corp. |
-0.01 4.55% |
0.10 | - | - | 66.65 | - | 95.30 | - |
| PINK Perimeter Medical Imaging AI Inc |
-0.02 11.11% |
0.16 | 4.13 | - | 18.78 | 11.34 | 20.22 | -2.55 |
| CHER Cheelcare Inc. |
-0.03 2.40% |
1.22 | - | - | 20.92 | 106.42 | 21.26 | - |
MedX Health Corp develops, manufactures, and markets skin related screening tools and phototherapy devices for pain relief and tissue repair in Canada, the United States, Europe, and internationally. The company offers SIAscopy, a medical device technology used to scan skin for suspicious moles and lesions; and phototherapeutic medical devices, which use light energy in lower-level laser and LED to provide treatment for pain and tissue damage in the rehabilitation market. It also provides scope kits, SIAscope, a clinical camera; and DermSecure, a telemedicine software application. In addition, the company offers MedX rehab console system, rehab portable laser, and home unit; OraLase, a dental PBM laser; and veterinary-specific lasers. MedX Health Corp was incorporated in 1999 and is headquartered in Mississauga, Canada.
| Name | Title | Year Born |
|---|---|---|
| Mr. Louie Canitano | COO & MD of Light Therapy Products | NA |
| Mr. Michael Druhan | Pres of Dermatological Services & Products | NA |
| Mr. Naman Demaghlatrous BAMA | Pres, CEO & Director | NA |
| C H Freeman | Interim Chief Financial Officer | NA |
| Mr. Paul Karam | Sales and Marketing Director of Europe, Middle East & Africa | NA |
| Dr. Daniel A. Kaute | Managing Director of Europe | NA |
| Mr. Scott Naughton | Managing Director of US Operations | NA |
| Mr. Christopher H. Freeman | Sec. | NA |
| Mr. Christopher H. Freeman | Corporate Secretary & Acting CFO | NA |
| Mr. Michael Druhan | President of Dermatological Services & Products | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.